ReviewExpert review of vaccines2016
Immune correlates for dengue vaccine development.
Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.Journal of virology · 2017Trial
- Design of a novel epitope-based tetravalent subunit vaccine against dengue virus: An immunoinformatic approach.PloS one · 2026Article
- Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.PLoS medicine · 2025Article
- Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice.Frontiers in immunology · 2023Article
- Temporal patterns of functional anti-dengue antibodies in dengue infected individuals with different disease outcome or infection history.Scientific reports · 2022Article
- Recent updates on correlates of vaccine-induced protection.Frontiers in immunology · 2022Article
- Review
- Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death.Heliyon · 2021Article
- Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.Signal transduction and targeted therapy · 2021Review
- Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques.Frontiers in immunology · 2021Article
- Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention.Vaccines · 2019Review
- Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy.American journal of public health · 2019Article
- Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.Scientific reports · 2018Article
- Article
- Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.Journal of virology · 2017Article
- Human CD4Journal of virology · 2017Article
- A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Dengue virus is the leading cause of vector-borne viral disease with four serotypes in circulation. Vaccine development has been complicated by the potential for both protection and disease enhancement during heterologous infection. Secondary infection triggers cross-reactive immune memory responses that have varying functional and epitope specificities that determine protection or risk. Strongly neutralizing antibodies to quaternary epitopes may be especially important for virus neutralization. Cell-mediated immunity dominated by Th1 functions may also play an important role. Determining an immune correlate of protection or risk would be highly beneficial for vaccine development but is hampered by mechanistic uncertainties and assay limitations. Clinical efficacy trials and human infection models along with a systems approach may provide future opportunities to elucidate such correlates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.